Granules (India) spikes up as USFDA completes audit of US subsidiary
DSIJ Intelligence / 11 Dec 2017
The stock of Granules (India) was buzzing on the bourses on Monday. The stock was up close to 5 per cent in intraday trade.
The stock of Granules (India) was buzzing on the bourses on Monday. The stock was up close to 5 per cent in intraday trade.
The facility of company's US-based subsidiary, Granules Pharmaceuticals, Inc. was inspected by USFDA with one observation. The plant is located in Chantilly, Virginia and the inspection was conducted in the second week of December.
Granules (India) reported standalone sales of Rs. 374 crore for the quarter ended September 2017. In this quarter, the company recorded EBITDA of Rs. 82 crore and PAT of Rs. 36 crore.
Granules (India) is a pharma manufacturing company that produces finished dosages (FDs), pharmaceutical formulation intermediates (PFIs) and active pharmaceutical ingredients (APIs).
At 11:59 hours, the stock was trading at Rs. 132.10 per share, up Rs. 5.05 or 3.97 per cent on Monday. Meanwhile, S&P BSE Sensex was at 33,362.60 points, up 112.30 points or 0.34 per cent.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.